Relay Therapeutics Inc reports a Return on Equity (ROE) of -42.47%.

What is RLAY's dividend yield?

Relay Therapeutics Inc offers a dividend yield of 0.00%.

What is RLAY's Quality Score?

Our AI rates RLAY's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy RLAY?

Our AI Timing Score for RLAY is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does RLAY belong to?

Relay Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Relay Therapeutics Inc (RLAY) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

RLAY AI Analysis Summary

Our AI summary for RLAY: Relay Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -42.47%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

RLAY

Relay Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 71

USD 18.78

-0.05 (-0.27%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-42.5%

ROE

-39.0%

ROA

0.00%

Div Yield

RELAY THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 18.78 Price -0.05 (-0.27%) Day Change	NEWS SCORE: 71

RLAY, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	71
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	18.78
PBV / Sector	6.39 / 44,219.29
Earning Per Share	-1.25

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	46.94 M GREAT
Average 1W Daily Value	32.11 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-2,554.14 / 98.22
NPM Average (%) / Sector	-6,020.84 / -1,697.63
NPM Change Average (%) / Sector	13.42 / 5,097.97 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-38.98 / 185,260.96
ROA Average (%) / Sector	-37.83 / 36,684.70
ROA Change Average (%) / Sector	12.86 / 422,221.66 GOOD
ROE (%) / Sector	-42.47 / 243,762.23
ROE Average (%) / Sector	-42.14 / 48,758.47
ROE Change Average (%) / Sector	10.90 / 424,968.10 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:02:05
Symbol	RLAY
Name	RELAY THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	217.94 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	4,103.82 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 60 Hampshire Street, Cambridge, MA, United States, 02139

Phone: 617 370 8837

Website: https://www.relaytx.com

Employees: 193

Sector: Healthcare >> Biotechnology

Description: Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.